A randomized, first-line study of tesevatinib monotherapy in patients with EGFR-mutant non-small cell lung cancer who present with CNS metastases

Trial Profile

A randomized, first-line study of tesevatinib monotherapy in patients with EGFR-mutant non-small cell lung cancer who present with CNS metastases

Planning
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Tesevatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Mar 2017 According to a Kadmon Corporation media release, the company expects to initiate this trial in the second quarter of 2017.
    • 13 Dec 2016 New trial record
    • 06 Dec 2016 According to a Kadmon media release, based on the interim results of another trial (see profile 264084) company is planning to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top